

- Group II: Claim 18-29, drawn to methods for modulating tumorigenicity by administration of oligonucleotides or ribozymes, classifiable in class 514, subclass 44;
- Group III: Claims 21-29, drawn to methods of inhibiting hydroxyurea resistant neoplastic cells or increasing sensitivity;
- Group IV: Claim 32, drawn to an antibody directed against the oligonucleotide corresponding to the R1 or R2 component of ribonucleotide reductase, classifiable in class 424, subclass 130.1; and
- Group V: Claims 33 and 34, drawn to a method for identifying a substance that binds to an oligonucleotide to modulate tumorigenicity or screening for an agonist or antagonist of the binding of an oligonucleotide and a substance, classifiable in class 435, subclass 6.

In response to this restriction requirement, Applicants elect, without traverse, to prosecute the invention defined by Group I, namely claims 1-17 and 30. In view of this election, Applicants have canceled Claims 18-29 and 32-34 without prejudice or disclaimer to file divisional applications directed to the subject matter of those claims.

Applicants also wish to bring to the Examiner's attention that Claim 31 was not discussed in the Restriction Requirement mailed June 5, 2000. Accordingly, Claim 31 has not been canceled.

Early examination on the merits is respectfully requested.

Respectfully submitted,  
BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Leslie J. Boley  
Registration No. 41,490

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650) 622-2300 (California Office)

Date: June 28, 2000